Chinook Therapeutics, Inc. Common Stock
KDNY
KDNY was delisted on the 10th of August, 2023.
94 hedge funds and large institutions have $273M invested in Chinook Therapeutics, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 35 increasing their positions, 23 reducing their positions, and 14 closing their positions.
129% more call options, than puts
Call options by funds: $461K | Put options by funds: $201K
52% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 23
29% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 14
4% more funds holding
Funds holding: 90 → 94 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
27% less capital invested
Capital invested by funds: $375M → $273M (-$102M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$19M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.03M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$4.69M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$4.27M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HMC
Harvard Management Company
Boston,
Massachusetts
|
-$20.5M |
| 2 |
O
OppenheimerFunds
New York
|
-$8.69M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$1.97M |
| 4 |
William Blair & Company
Chicago,
Illinois
|
-$1.08M |
| 5 |
AC
Ascend Capital
Orinda,
California
|
-$1.08M |
KDNY Hedge Fund Activity: Q4 2017 in Review
94 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q4 2017, worth a combined $273M — down 27% from $375M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new KDNY positions and 14 closed out — a net gain of 4 holders — while 35 added to existing stakes and 23 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $19M. The largest seller was Harvard Management Company, cutting an estimated $20.5M.
- 94 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q4 2017, up from 90 in Q3 2017.
- Funds reported $273M of Chinook Therapeutics, Inc. Common Stock stock for Q4 2017, down 27% quarter-over-quarter.
- 18 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q4 2017 and 14 closed out, a net change of +4 holders.
- The largest Chinook Therapeutics, Inc. Common Stock buyer in Q4 2017 was Point72 Asset Management, an estimated $19M added.
- The largest Chinook Therapeutics, Inc. Common Stock seller in Q4 2017 was Harvard Management Company, an estimated $20.5M sold.
Based on aggregated 13F filings for Q4 2017.